Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116945 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| Iodide SCHEMBL11812745 | 0.98 | CYP3A4 (0.96) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL1000639 | 0.98 | CYP3A4 (0.96) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL6065407 | 0.85 | CYP3A4 (0.72) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL9746696 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| Acrylamide SCHEMBL6582120 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL619775 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL29557996 | 0.83 | CYP3A4 (0.70) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| SCHEMBL9284399 | 0.82 | LMNA (0.68) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 | |
| Methane SCHEMBL27204481 | 0.81 | CYP3A4 (0.68) | CYP3A4CYP2D6LMNACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| US-20240182482-A1 | FUSED CYCLIC COMPOUND AS WEE-1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-06-06 | — | — | US | disclosed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| EP-4332104-A1 | FUSED RING COMPOUND AS WEE-1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117377671-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182482-A1 | FUSED CYCLIC COMPOUND AS WEE-1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, WASF2 | CYP3A4 1906/4885CYP2D6 2299/4885LMNA 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.